MA50532A - Compositions et méthodes pour le traitement de cancers - Google Patents

Compositions et méthodes pour le traitement de cancers

Info

Publication number
MA50532A
MA50532A MA050532A MA50532A MA50532A MA 50532 A MA50532 A MA 50532A MA 050532 A MA050532 A MA 050532A MA 50532 A MA50532 A MA 50532A MA 50532 A MA50532 A MA 50532A
Authority
MA
Morocco
Prior art keywords
cancers
compositions
treatment
methods
Prior art date
Application number
MA050532A
Other languages
English (en)
Inventor
Costa Pinheiro Pedro Filipe Da
Mark Kester
Jeremy Shaw
Original Assignee
Univ Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Patent Foundation filed Critical Univ Virginia Patent Foundation
Publication of MA50532A publication Critical patent/MA50532A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050532A 2017-11-03 2018-11-05 Compositions et méthodes pour le traitement de cancers MA50532A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762581179P 2017-11-03 2017-11-03

Publications (1)

Publication Number Publication Date
MA50532A true MA50532A (fr) 2020-09-09

Family

ID=66332377

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050532A MA50532A (fr) 2017-11-03 2018-11-05 Compositions et méthodes pour le traitement de cancers

Country Status (4)

Country Link
US (1) US12343428B2 (fr)
EP (1) EP3703653A4 (fr)
MA (1) MA50532A (fr)
WO (1) WO2019090255A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020154716A1 (fr) * 2019-01-26 2020-07-30 University Of Rochester Compositions et méthodes de traitement du cancer de la prostate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026831A1 (en) 2001-04-20 2003-02-06 Aparna Lakkaraju Anionic liposomes for delivery of bioactive agents
EP1601344A2 (fr) 2003-03-07 2005-12-07 Celator Technologies Inc. Transfert ameliore de sphingolipides
WO2004087097A2 (fr) 2003-03-31 2004-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ensembles de lipides contenant des amphiphiles de formation non liposomique
KR20060015534A (ko) 2003-04-25 2006-02-17 더 펜 스테이트 리서치 파운데이션 성장 억제, 지질 유래된 생활성 화합물의 전신 전달을 위한방법 및 시스템
MXPA06010667A (es) 2004-03-19 2007-07-04 Penn State Res Found Metodos combinatorios y composiciones para el tratamiento de melanoma.
WO2008006046A1 (fr) 2006-07-06 2008-01-10 Case Western Reserve University Composition de céramide et utilisation pour le traitement de maladies oculaires
SG184127A1 (en) * 2010-03-19 2012-10-30 Massachusetts Inst Technology Lipid vesicle compositions and methods of use
WO2012088414A1 (fr) 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Formulation liposomale de céramides non-glycosidiques et leurs utilisations
SG2014010409A (en) 2011-05-10 2014-05-29 Penn State Res Found Ceramide anionic liposome compositions
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
WO2014144421A1 (fr) * 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Inversion de céramide de la résistance à plusieurs médicaments
US20150157646A1 (en) * 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
WO2016033527A1 (fr) * 2014-08-29 2016-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulation immunogène par thérapie de privation endocrinienne permettant d'améliorer la sensibilité de cellules tumorales à une lyse à médiation immunitaire
CN104922067A (zh) * 2014-12-08 2015-09-23 上海张江生物技术有限公司 一种载药纳米脂质体、制备方法及用途
EP3352753A4 (fr) 2015-09-24 2019-03-13 The Regents of The University of California Molécules de type sphingolipide synthétiques, médicaments, procédés pour leur synthèse et procédés de traitement

Also Published As

Publication number Publication date
US20200268665A1 (en) 2020-08-27
EP3703653A4 (fr) 2021-09-08
WO2019090255A1 (fr) 2019-05-09
US12343428B2 (en) 2025-07-01
EP3703653A1 (fr) 2020-09-09

Similar Documents

Publication Publication Date Title
EP3368559A4 (fr) Compositions et méthodes pour le du traitement du cancer
EP3687981A4 (fr) Compositions et méthodes de traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
EP3462883A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3801578A4 (fr) Méthodes et compositions pour le traitement de c. difficile
EP3347025A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3288383A4 (fr) Méthodes de traitement du cancer
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
EP3638293A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l'hyperhidrose
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l'acné
EP3353204A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3471722A4 (fr) Composés et méthodes pour la prévention et/ou le traitement du cancer
EP3365014A4 (fr) Méthodes et compositions pour le traitement de la mastocytose systémique
EP3478284A4 (fr) Composés et compositions pour le traitement du cancer
EP3522865A4 (fr) Méthodes et compositions pour le traitement de vergetures
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose